Pacira BioSciences, Inc. PCRX Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total net product sales by Product | ||||||
| Bupivacaine liposome injectable suspension | $5.47M-26.1% | $6.91M-5.6% | $5.8M-31.1% | $4.76M-37.7% | $7.4M+42.9% | |
| EXPAREL | $581.88M+5.2% | $575.13M+4.8% | $567.02M+4.0% | $559.13M+3.2% | $553.06M+2.4% | |
| iovera° | $25.23M+10.2% | $24.18M+6.0% | $23.63M+5.5% | $22.82M+3.7% | $22.91M+10.6% | |
| ZILRETTA | $120.06M+3.9% | $116.63M-1.2% | $116.78M+2.7% | $116.22M+1.9% | $115.59M+2.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Pacira BioSciences, Inc. break its business down?
- Pacira BioSciences, Inc. (PCRX) reports total net product sales by product across 4 parts — Bupivacaine liposome injectable suspension, EXPAREL, iovera° and ZILRETTA. Each is extracted from the segment footnotes and tracked over time.
- Where does Pacira BioSciences, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Pacira BioSciences, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
